Ocular Therapeutix (OCUL) Other financing activities (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Other financing activities of $1.7 million for Q2 2026, down 45.27% year-over-year from $3.1 million in Q2 2025, and up 471.09% on a QoQ basis from $294000.0 in Q1 2026.
Ocular Therapeutix (OCUL) Other financing activities (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Other financing activities for 14 years, with the latest figure at $1.7 million in Q2 2026.
- Other financing activities for Q2 2026 came in at $1.7 million, down 45.27% year-over-year; the trailing twelve-month figure through Jun 2026 was $15.3 million (up 110.54% YoY), and the FY2025 annual result was $20.5 million, down 93.51% from the prior year.
- Other financing activities improved to $1.7 million in Q2 2026, from $294000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $316.4 million in Q1 2024 and troughed at $32000.0 in Q3 2022.
- A 5-year average of $24.6 million and a median of $1.1 million in 2022 frame the typical range for Other financing activities.
- The widest annual swing landed in 2024, when Other financing activities soared 405480.77%; it then slumped 98.68% in 2025.
- A 5-year view of Other financing activities shows it stood at $426000.0 in 2022, then surged by 1003.99% to $4.7 million in 2023, then jumped by 6626.62% to $316.4 million in 2024, then sank by 99.07% to $2.9 million in 2025, then plunged by 42.83% to $1.7 million in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $1.7 million in Q2 2026, $294000.0 in Q1 2026, and $2.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Jun 30, 2026 | 1.68 Mn |
| Mar 31, 2026 | 294,000.00 |
| Mar 31, 2026 | 294,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Sep 30, 2025 | -6.54 Mn |
| Sep 30, 2025 | -6.54 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Mar 31, 2025 | 4.18 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Dec 31, 2024 | 14.25 Mn |
| Sep 30, 2024 | -6.08 Mn |
| Sep 30, 2024 | -6.08 Mn |
| Jun 30, 2024 | -309.78 Mn |
| Jun 30, 2024 | -309.78 Mn |
| Mar 31, 2024 | 316.35 Mn |
| Mar 31, 2024 | 316.35 Mn |